TL;DR: Tilray Brands (Nasdaq: TLRY) reported record fiscal third-quarter revenue of $206.7 million for the period ending February 28, 2026, up 11% year-over-year, driven by a 73% surge in international cannabis revenue and steady gains across its Canadian and wellness segments. The company posted its first meaningful adjusted net income and reaffirmed full-year fiscal 2026 guidance. The post-quarter BrewDog acquisition further diversifies Tilray’s global consumer platform.
Market Analysis
Tilray’s Q3 FY2026 results mark the company’s strongest third-quarter performance on both a revenue and gross profit basis in its operating history. Cannabis net revenue rose 19% year-over-year to $64.8 million, with the international segment the primary driver — posting 73% growth and a record quarterly high. Canadian adult-use and medical cannabis combined grew 8% year-over-year, maintaining Tilray’s #1 revenue-share position in the Canadian market.
Key financial metrics from the quarter: Adjusted EBITDA increased 19% to $10.7 million ($9.0 million in the prior year period). Net loss improved a striking 97% to $25.2 million versus $793.5 million a year earlier, with net loss per share improving to $(0.24) from $(8.69). The company achieved $2.4 million in adjusted net income — a rare positive adjusted earnings print for any cannabis LP. Distribution net revenue hit a record $83.0 million (from $61.5 million), driven by the Tilray Pharma pharmaceutical distribution business in Europe.
The balance sheet remains a comparative strength: $264.8 million in cash and marketable securities, with a net cash position of $3.5 million — representing a $40.2 million year-over-year improvement from a prior net debt position of $36.6 million. For cannabis sector investors tracking multi-year financial trends, monitor TLRY alongside sector peers at the cannabis stock tracker.
Context & Regulatory Backdrop
Tilray operates at the intersection of multiple regulatory environments — Canadian federal legalization, EU medical cannabis frameworks, and U.S. beverage markets — giving it a differentiated profile relative to U.S.-focused MSOs. The Company’s diversified model spans four business lines: cannabis (Canada + international), craft beverage, Tilray Pharma distribution, and wellness (hemp-derived products). This structure provides revenue resilience during periods of cannabis market volatility and regulatory uncertainty in the U.S.
The completion of Project 420 — Tilray’s internal cost restructuring initiative — delivered approximately $33 million in annualized savings within the beverage segment, partially offsetting the sequential margin compression seen in that division. Beverage net revenue came in at $42.6 million versus $55.9 million in the prior year period, with gross margin declining to 32% from 36%, reflecting ongoing competitive pressure in the North American craft beer market.
Post-quarter, Tilray closed the BrewDog acquisition for approximately £40 million — adding the UK’s leading craft beer brand and distribution infrastructure across Europe, the Middle East, Australia, and Asia-Pacific. A separately announced 2027 Carlsberg distribution partnership broadens the European commercial reach further. These moves reflect CEO Irwin Simon’s stated thesis: build a global multi-category consumer platform that can capture growth across markets as cannabis regulation evolves worldwide.
Forward-Looking View
Tilray enters Q4 FY2026 with operational momentum, an improving balance sheet, and two high-profile beverage acquisitions in integration mode. The critical watch items for investors are: (1) BrewDog integration margin contribution in Q4 and FY2027, (2) continued international cannabis revenue growth trajectory — can the 73% YoY pace of Q3 be sustained or is this peak growth? — and (3) the resolution of U.S. rescheduling, which could unlock TLRY’s optionality in the U.S. cannabis market through its existing Medterra wellness brand and potential future investments.
At a $206.7 million quarterly run rate with improving EBITDA and a positive adjusted net income print, Tilray remains one of the more fundamentally credible names in the cannabis LP universe. For investors seeking international cannabis exposure with beverage diversification, TLRY’s execution in Q3 FY2026 provides a constructive data point — though beverage margin trajectory and BrewDog integration execution will be the near-term determinants of multiple expansion or compression.